All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
During the EHA 2022 Congress, the GvHD Hub was pleased to speak to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE. We asked, What is the role of human beta-defensin-2 (HBD-2) in modulation of the microbiome and acute GvHD (aGvHD)?
What is the role of human beta-defensin-2 in modulation of the microbiome and aGvHD?
Zeiser begins by discussing the high frequency of patients who develop aGvHD despite receiving prophylaxis. Zeiser also talks about the antimicrobial, immunosuppressive, and immunomodulatory functions of HBD-2, and how it can affect GvHD development and severity.
Subscribe to get the best content related to GvHD delivered to your inbox